-Member Login

Forgot your USERNAME OR PASSWORD?

Let's Stay Connected

Find us on the popular social networks

Facebook Twitter LinkedIn Flicker
  • About the Division

    The Division for Cancer Pharmacology (DCP) serves members with interests in all aspects of basic and translational cancer pharmacology research. Specific areas include, (but are not limited to) discovery and preclinical development of new anticancer agents, preclinical toxicology and adverse reactions to anticancer drugs, technical developments in novel cancer-related target and therapeutic identification, mechanisms of anticancer drug resistance, mechanistic studies of novel therapeutic regimens, pharmacogenetics of anticancer therapeutics, and biomarker studies in anticancer drug response.

     


    Division News

  • 2017 Division for Cancer Pharmacology Award Winners

    Congratulations to the 2017 winners of the Division for Cancer Pharmacology awards.

    EB2017 Division for Cancer Pharmacology Program-at-a-Glance

    The Division of Cancer Pharmacology (DCP) cordially invites you to join us at the ASPET annual meeting at EB2017.

    Letter from the Executive Committee

    We write to alert you to activities of the Division for Cancer Pharmacology (DCP), a new member division of The American Society for Pharmacology and Experimental Therapeutics (ASPET) and, if you haven’t already done so, to encourage you and other colleagues to join ASPET and the new cancer pharmacology division.

    Division for Cancer Pharmacology Fall 2016 Newsletter

    The Fall 2016 edition of the Division for Cancer Pharmacology Newsletter is now available. View it now in PDF.  

  • Right Rail DCP   
  • Division Goals

     

    • To increase outreach efforts with the goal of increasing membership from both academia and industry and their participation in ASPET meetings
    •  
    • To develop networking strategies for the benefit of junior and senior investigators
    •  
    • To increasing participation of industry-associated members in development of symposia for EB
    •  
    • To develop programming ideas including workshops addressing current challenges in cancer pharmacology (e.g. reproducibility and relevance of animal models of cancer)